CN107198718A - A kind of Chinese medicine composition of external curing fash and its preparation method and application - Google Patents
A kind of Chinese medicine composition of external curing fash and its preparation method and application Download PDFInfo
- Publication number
- CN107198718A CN107198718A CN201710307137.5A CN201710307137A CN107198718A CN 107198718 A CN107198718 A CN 107198718A CN 201710307137 A CN201710307137 A CN 201710307137A CN 107198718 A CN107198718 A CN 107198718A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- medicine composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The present invention provides a kind of Chinese medicine composition of external curing fash, and the bulk drug composition of the Chinese medicine composition is：The parts by weight of radix scutellariae 10~50, the parts by weight of purslane 10~60, the parts by weight of dittany bark 10~60, the parts by weight of kuh-seng 10~50, the parts by weight of dandelion 10~60.Chinese medicine composition of the present invention effect in terms of the related acneform eruptionses of EGFRIs and itch degree is improved is notable, and without obvious adverse reaction.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and its preparation method and application, and in particular to a kind of external curing fash
Chinese medicine composition and its preparation method and application, belongs to technical field of Chinese medicine.
Background technology
In recent years, the targeted therapy of tumour increases year by year in clinical application, and the therapeutic action of performance also increasingly increases, i.e.,
The 21 century promising oncotherapy mode of tool will be turned into.Most commonly used current clinical practice is that EGF-R ELISA is short of money
Anti-agent (epidermal growth factor receptor inhibitors, EGFRIs) class medicine, such medicine is protruded with it
Clinical efficacy and enjoy the favor of doctor and patient.But its adverse reaction performance is various, and fash (is mainly shown as acne/Cuo
Sore sample fash) it is wherein most commonly seen.Acne/acneform eruptions not only influences the quality of life of patient, and may cause
Treatment can not be normally carried out, and have a strong impact on the therapeutic effect of tumour.Acne/acneform eruptions is limited to a certain extent
The application of EGFRIs class medicines.The doctor trained in Western medicine often method treatment such as application antibiotic, external application hormone, effect is not very obvious.
The content of the invention
It is an object of the invention to provide a kind of Chinese medicine composition of external curing fash；
It is another object of the present invention to provide the preparation method of the Chinese medicine composition；
Third object of the present invention is to provide application of the Chinese medicine composition in external curing fash medicine is prepared.
Fourth object of the present invention is that providing the Chinese medicine composition is preparing the related fash medicines of external curing EGFRIs
Application in thing.
The purpose of the present invention is achieved by the following technical solution：
A kind of Chinese medicine composition of external curing fash, the bulk drug of the Chinese medicine composition, which is constituted, is：Radix scutellariae, purslane,
Dittany bark, kuh-seng, dandelion.
Further, the bulk drug composition of the Chinese medicine composition is：The parts by weight of radix scutellariae 10~50, the weight of purslane 10~60
Part, the parts by weight of dittany bark 10~60, the parts by weight of kuh-seng 10~50, the parts by weight of dandelion 10~60.
Further, the bulk drug composition of the Chinese medicine composition is：The parts by weight of radix scutellariae 12~45, the weight of purslane 15~55
Measure part, the parts by weight of dittany bark 15~55, the parts by weight of kuh-seng 12~45, the parts by weight of dandelion 15~55.
Further, the bulk drug composition of the Chinese medicine composition is：The parts by weight of radix scutellariae 15~40, the weight of purslane 20~50
Measure part, the parts by weight of dittany bark 20~50, the parts by weight of kuh-seng 15~40, the parts by weight of dandelion 20~50.
Further, the bulk drug composition of the Chinese medicine composition is：The parts by weight of radix scutellariae 18~35, the weight of purslane 25~45
Measure part, the parts by weight of dittany bark 25~45, the parts by weight of kuh-seng 18~35, the parts by weight of dandelion 25~45.
Further, the bulk drug composition of the Chinese medicine composition is：The parts by weight of radix scutellariae 20, the parts by weight of purslane 30, in vain
The parts by weight of moss skin 30, the parts by weight of kuh-seng 20, the parts by weight of dandelion 30；
Or, the parts by weight of radix scutellariae 25, the parts by weight of purslane 40, the parts by weight of dittany bark 35, the parts by weight of kuh-seng 30, the weight of dandelion 35
Measure part；
Or, the parts by weight of radix scutellariae 30, the parts by weight of purslane 35, the parts by weight of dittany bark 40, the parts by weight of kuh-seng 25, the weight of dandelion 40
Measure part.
The preparation method of Chinese medicine composition of the present invention is：
Each bulk drug is taken in proportion, and with water or organic solvent, routinely extracting method is extracted, and routinely preparation process system
It is standby into external preparation.
Above-mentioned general extraction methods include any one in refluxing extraction, Soakage extraction, ultrasonic extraction or seepage pressure effects
Mode, or Different Extraction Method combination；The organic solvent is one in methanol, 20~95% ethanol solution, acetone
Plant or several.The exterior-applied formulation includes patch, cataplasm, ointment, plaster, gel, liniment, lotion, plastics etc..
In the form of Chinese medicine composition of the present invention with radix scutellariae, purslane, dittany bark, kuh-seng, dandelion crude drug except being fed intake
Outside, it can also use in the form of the extract (active component) of above-mentioned crude drug feeds intake, therefore the present invention further discloses
A kind of Chinese medicine composition of external curing fash：
A kind of Chinese medicine composition of external curing fash, the Chinese medicine composition is made up of the following raw material medicine：Baical Skullcap root P.E
10~50 parts by weight, the parts by weight of purslane extract 10~60, the parts by weight of dittany bark extract 10~60, shrubby sophora extract 10~
50 parts by weight, the parts by weight of dandelion extract 10~60.
Further, the Chinese medicine composition is made up of the following raw material medicine：The parts by weight of Baical Skullcap root P.E 20, purslane extract 30
Parts by weight, the parts by weight of dittany bark extract 30, the parts by weight of shrubby sophora extract 20, the parts by weight of dandelion extract 30；
Or, the parts by weight of Baical Skullcap root P.E 25, the parts by weight of purslane extract 40, the parts by weight of dittany bark extract 35, kuh-seng
The parts by weight of extract 30, the parts by weight of dandelion extract 35；
Or, the parts by weight of Baical Skullcap root P.E 30, the parts by weight of purslane extract 35, the parts by weight of dittany bark extract 40, kuh-seng
The parts by weight of extract 25, the parts by weight of dandelion extract 40.
Above-mentioned raw materials medicament extract can be the water extract of each bulk drug, or extractive with organic solvent, or water extract/organic
Solvent extractable matter passes through the refined thing that further polishing purification technique is obtained.
One or more of the organic solvent in methanol, 20~95% ethanol solutions, acetone；
Preparing the extracting method used in said extracted thing includes refluxing extraction, Soakage extraction, ultrasonic extraction or seepage pressure effects
In any one mode, or Different Extraction Method combination.
Each bulk drug radix scutellariae of the present composition, purslane, the root bark of shaggy-fruited dittany, kuh-seng, dandelion meet 2015 editions《Middle traditional Chinese medicines
Allusion quotation》Record；And the content of baicalin in Scutellaria baicalensis Georgi is that general flavone content is 0.5-2.5%, shaggy-fruited dittany in 0.2-4.5%, purslane
Matrine content is that general flavone is 0.1-2.2% in 1-10%, dandelion in general flavone content 0.1-2.5%, kuh-seng in skin.
It is present invention also offers application of the Chinese medicine composition in external curing fash medicine is prepared and outer preparing
With the application in the related fash medicines for the treatment of EGFRIs.
Clinical experimental study result shows, traditional Chinese medicine composition for treating fash classification of the present invention, pruitus, dry skin
Effective percentage is respectively 90.1%, 57.9%, 57.9%；Control group is respectively 12.9%, 28.6%, 1.6%.Two groups are compared fash
Classification, pruitus, the difference of dry skin are statistically significant.
Brief description of the drawings
One week fash situation of change before and after Fig. 1 patient medications
A is before medication, B is after medication
Clinical effectiveness of the present composition of experimental example 1 to the related fash of EGFRIs
Enter the related fash patient 201 of group EGFRIs altogether from January, 2013 in August, 2015, complete clinical observation totally 185
Example.It is China-Japan Friendship Hospital's combination of Chinese tradiational and Western medicine oncology, PLA General Hospital oncology, BJ Chest Science Hospital's oncology, court
Positive hospital's oncology outpatient service or ward case make a definite diagnosis the patient of malignant tumour.Wherein China-Japan Friendship Hospital's experimental group enters group 62,
Control group enters group 35；PLA General Hospital experimental group enters group 35, and control group enters group 18；BJ Chest Science Hospital's experimental group is real
Test group and enter group 30, control group enters group 15；ZhaoYang Hospital enters group 4, and control group enters group 2.
1. diagnostic criteria：
Through the clear and definite malignant tumor patient of pathological diagnosis, acne sample fash after EGFRIs is used.
2. acneform eruptions grade scale
The order of severity evaluation of acneform eruptions, manages cooperative groups to evaluate EGFRIs using U.S.'s dermal toxicity
Related dermal reacts MASCC grade scales, is specifically shown in Table 1：
The MASCC grade scales of table 1
* be separated by between fash >=2cm is calculated as at 2.
3. pruitus, dry skin hierarchical application NCI-CTCAE standards (3.0 editions), are shown in Table 2.
The EGFRIs related dermal adverse reaction NCI-CTCAE standards (3.0 editions) of table 2
4. inclusion criteria
1. there is the malignant tumor patient of clear and definite pathological diagnosis；2. EGFRIs treatments and acne sample fash are being carried out
Person；Or take the appearance of other molecular targeted agents and the EGFRIs skin damaged persons of behaving like；3. the heart, Liver and kidney function are without serious hindrance；
4. age 18-80 Sui；5. without intelligence and phrenoblabia, ability of language expression is normal；6. understand and receive this treatment, signature is known
Feelings letter of consent.
5. exclusion standard
1. treatment EGFRIs and other molecular targeted agents person have been stopped.2. non-acne sample fash person.3. only show
Reacted for other type-skins, such as dry skin, paronychia and schizonychia.4. allergic constitution person.
6. treatment method：
Experimental group：The preparation prepared by the method for embodiment 1, continuous application 7-14 days.
Application method：Facial area：Facial mask is made in the preparation of embodiment 1, it is 30 minutes every time, daily 2-3 times, after the completion of use
Clear water is cleaned.
Head fash：The preparation of embodiment 1 is directly applied to fash position outside, it is 30 minutes every time, daily 2-3 times, complete
Cleaned afterwards with clear water.Secretion please don't strongly be removed.
Other positions：The preparation of embodiment 1 is directly applied to fash position outside, it is 30 minutes every time, daily 2-3 times, complete
Cleaned afterwards with clear water.
If fash is extensively, it can be added with said preparation in water for bathing, foam washing 30 minutes before sleeping.
Control group：Slight fash gives erythromycin emulsifiable paste external application, and diphenhydramine frost is given (by Sino-Japan friendly doctor with itch person
Institute Drug Manufacturing Room provide)；Mild skin rashes give erythromycin emulsifiable paste external application, and it is oral 2 times a day to give minocycline 100mg；Severe
Fash gives processing with severe fash, and it is oral 2 times a day that such as concurrent infection gives cefuroxime 250mg, if skin symptom continues
It can not alleviate, be considered as EGFRIs class medicine decrements or even disable.
Placebo facial mask and external medicinal liquid are given simultaneously, is used in conjunction 7-14 days
7. the standard of curative effect evaluation：
Recovery from illness：Schultz-Charlton, no subjective symptom, without infection sign, normal life, work.
Take a turn for the better：Dermal toxicity classification declines one-level and above person, and (including fash is significantly reduced or from being changed into local point extensively
Cloth, subjective symptom mitigate or disappeared, quality of life is obviously improved).
It is invalid：Fash is unchanged or toxicity grading going up one level and above person (including fash showed increased or by locally becoming
For whole body it is widely distributed, there is subjective symptom or exacerbation, quality of life substantially deteriorate).
Total effective rate (%)=(recovery from illness+improvement)/total number of cases × 100%
8. result of the test
Fash changed in stages before and after 8.1 treatments：Effective 109 of experimental group, stablizes 10, invalid 2；Control group effective 9
Example, stablizes 40, invalid 15.Through statistical test, change of the experimental group fash classification through treatment 14 days is that have statistics meaning
Justice, effective percentage is 90.1%；Change of the control group fash classification through treatment 14 days is insignificant.Experimental group is improving fash
Curative effect in classification is better than control group (being shown in Table 3).
The experimental group of table 3 is classified the comparitive study before and after treatment with control group fash
| Fash is classified | n | Effectively | It is stable | It is invalid | Chi-square value | P |
| Experimental group | 121 | 109 | 10 | 2 | - | - |
| Control group | 64 | 9 | 40 | 15 | 105.1022 | ＜ 0.0001 |
Through non-parametric test, after experimental group is treated 14 days with control group, the comparitive study P ＜ 0.05 of fash classification, difference
It is statistically significant.The curative effect of experimental group is better than control group.
Pruitus indexing change before and after 8.2 treatments：Effective 70 of experimental group, stablizes 46, invalid 5；Control group has
Effect 4, stablizes 35, invalid 18.Through statistical test, change of the experimental group pruitus through treatment 14 days is meaningful
, effective percentage is 57.9%；Change of the control group pruitus through treatment 14 days is insignificant.Experimental group is improving skin scabies
Curative effect on itching is better than control group (being shown in Table 4).
The experimental group of table 4 treats front and rear comparitive study with control group pruitus
| Itch | n | Effectively | It is stable | It is invalid | Chi-square value | P |
| Experimental group | 121 | 70 | 46 | 5 | - | - |
| Control group | 64 | 4 | 35 | 18 | 51.3312 | ＜ 0.0001 |
Through non-parametric test, after experimental group is treated 14 days with control group, the comparitive study P ＜ 0.05 of pruitus, difference
It is statistically significant.The curative effect of experimental group is better than control group.
(3) dry skin indexing change before and after treating：Effective 70 of experimental group, stablizes 46, invalid 5；Control group has
Effect 1, stablizes 40, invalid 17.Through statistical test, change of the experimental group dry skin through treatment 14 days is meaningful
, effective percentage is 57.9%；Change of the control group dry skin through treatment 14 days is insignificant.Experimental group is done in improvement skin
Curative effect on dry is better than control group (being shown in Table 5).
The comparitive study of indexing before and after the experimental group of table 5 is treated with control group dry skin
| Dry | n | Effectively | It is stable | It is invalid | Chi-square value | P |
| Experimental group | 121 | 70 | 46 | 5 | - | - |
| Control group | 64 | 1 | 40 | 17 | 59.1777 | ＜ 0.0001 |
Through non-parametric test, after experimental group is treated 14 days with control group, the comparitive study P ＜ 0.05 of dry skin, difference
It is statistically significant.The curative effect of experimental group is better than control group.
Enter group 201,185 completion clinical observations, test group comes off 10, control group 6.Its experimental group treats fash
Classification, pruitus, the effective percentage of dry skin are respectively 90.1%, 57.9%, 57.9%；Control group is respectively 12.9%,
28.6%th, 1.6%.Two groups are compared fash classification, pruitus, the statistically significant (χ of the difference of dry skin2Respectively
105.1022,51.3312,59.1777, P ＜ 0.05).Do not occur the serious bad thing related to medicine during clinical observation
Part, preferably, test group and control group satisfaction are respectively 95.40%, 65.50% to security.Two groups of progression free survival phase differences
Not statistically significant (χ2=2.006, P ＞ 0.05).
Patient goes into business certain, and facial rash, shirtfront, back fash occurs in man, adenocarcinoma of lung after taking Tarceva 1 week, Fig. 1 is
Useless fellow is collapsed after the situation of change of one week after before medication, medication one week, and fash is reduced, and color of the leather is clearly better, and itch is alleviated.
Embodiment
Embodiment 1
Prescription：Radix scutellariae 20g, purslane 30g, dittany bark 30g, kuh-seng 20g, dandelion 30g；
The baicalin in Scutellaria baicalensis Georgi content is that Flavonoids in Portulaca Oleracea L is white in 2%, dittany bark in 2.5%, purslane
Moss skin general flavone content is that matrine content is that the content of total Flavonoids from Taraxacum mongolicum in 2%, dandelion is 1.8% in 2%, kuh-seng.
Each component content assay method is respectively referred to above《Chinese Pharmacopoeia》2015 editions radix scutellariaes, purslane, the root bark of shaggy-fruited dittany, kuh-seng, dandelions
Content assaying method under is measured.
Preparation method：Bulk drug being taken in proportion, decocting is boiled twice, merging extract solution, filtering is concentrated under reduced pressure into density 1.10
(60 DEG C), high speed centrifugation takes supernatant；According to supernatant: glycerine: close=2.2: 1: 2 ratio adds auxiliary material, and external application system is made
Agent.
Use homogeneous tank homogeneous：Rated pressure 0-100Mpa, metered flow 30kg/ minutes, rated temperature is less than in 60 degree.
Usage：It is applied to fash position outside directly or facial mask is made and is affixed on face.
Embodiment 2
Prescription：Radix scutellariae 25g, purslane 40g, dittany bark 35g, kuh-seng 30g, dandelion 35g；
Preparation method：Bulk drug being taken in proportion, 50% alcohol reflux is extracted twice, merging extract solution, second is reclaimed in filtering
Alcohol, is dissolved in water, and is concentrated under reduced pressure into density 1.10 (60 DEG C), high speed centrifugation takes supernatant；According to supernatant: glycerine: close=
2.2: 1: 2 ratio adds auxiliary material, and external preparation is made.
Usage：It is applied to fash position outside directly or facial mask is made and is affixed on face.
Embodiment 3
Prescription：Radix scutellariae 30g, purslane 35g, dittany bark 40g, kuh-seng 25g, dandelion 40g；
Preparation method be the same as Example 1.
Embodiment 4
Prescription：Radix scutellariae 15g, purslane 50g, dittany bark 20g, kuh-seng 40g, dandelion 20g.
Embodiment 5
Prescription：Radix scutellariae 40g, purslane 20g, dittany bark 50g, kuh-seng 15g, dandelion 50g.
Embodiment 6
Prescription：Radix scutellariae 10g, purslane 60g, dittany bark 10g, kuh-seng 50g, dandelion 10g.
Embodiment 7
Prescription：Radix scutellariae 50g, purslane 10g, dittany bark 60g, kuh-seng 10g, dandelion 60g.
Embodiment 8
Prescription：Baical Skullcap root P.E 20g, purslane extract 30g, dittany bark extract 30g, shrubby sophora extract 20g, Pu Gong
English extract 30g；
The extract is respectively the water extract that bulk drug is obtained through water extraction.
Embodiment 9
Prescription：Baical Skullcap root P.E 25g, purslane extract 40g, dittany bark extract 35g, shrubby sophora extract 30g, Pu Gong
English extract 35g；
The extract is respectively that bulk drug extracts obtained ethanol extract through 50% ethanol solution.
Embodiment 10
Prescription：Baical Skullcap root P.E 30g, purslane extract 35g, dittany bark extract 40g, shrubby sophora extract 25g, Pu Gong
English extract 40g.
The extract is respectively the water extract that bulk drug is obtained through water extraction.
Embodiment 11
Prescription：Radix scutellariae 20g, purslane 30g, dittany bark 30g, kuh-seng 20g, dandelion 30g, radix paeoniae rubrathe 15g, peppermint 5g；
Preparation method：Bulk drug being taken in proportion, decocting is boiled twice, merging extract solution, filtering is concentrated under reduced pressure into density 1.10
(60 DEG C), high speed centrifugation takes supernatant；According to supernatant: glycerine: close=2.2: 1: 2 ratio adds auxiliary material, and external application system is made
Agent.
Use homogeneous tank homogeneous：Rated pressure 0-100Mpa, metered flow 30kg/ minutes, rated temperature is less than in 60 degree.
Usage：It is applied to fash position outside directly or facial mask is made and is affixed on face.
The clinical effectiveness of preparation prepared by comparing embodiment 1 and embodiment 11 to the related fash of EGFRIs
Experimental group 1：Preparation prepared by embodiment 11；
Experimental group 2：Preparation prepared by embodiment 1；
Two groups are respectively included 3 degree of fash patients 121 (grade scale is shown in Table 1), after treatment 14 days, the change of fash classification
Situation is shown in Table 6.
The related fash of 6 two groups of preparation for treating EGFRIs of table situation of change after 14 days
| Group | 1A | 1B | 2A | 2B | 3A | 3B | Chi-square value | P |
| Experimental group 1 | 3 | 9 | 21 | 32 | 31 | 25 | - | —— |
| Experimental group 2 | 8 | 16 | 47 | 22 | 26 | 2 | 7.2808 | 0.007 |
Through Chi-square Test, fash changed in stages P ＜ 0.05 after two groups of treatments 14 days, difference is statistically significant.Illustrate real
Apply the prescription effect of example 1 and be significantly better than the prescription of embodiment 11.
Claims (10)
1. a kind of Chinese medicine composition of external curing fash, it is characterised in that the bulk drug of the Chinese medicine composition, which is constituted, is：It is yellow
A kind of reed mentioned in ancient books, purslane, dittany bark, kuh-seng, dandelion.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that the bulk drug of the Chinese medicine composition, which is constituted, is：It is yellow
The parts by weight of a kind of reed mentioned in ancient books 10~50, the parts by weight of purslane 10~60, the parts by weight of dittany bark 10~60, the parts by weight of kuh-seng 10~50, dandelion
10~60 parts by weight.
3. Chinese medicine composition as claimed in claim 2, it is characterised in that the bulk drug of the Chinese medicine composition, which is constituted, is：It is yellow
The parts by weight of a kind of reed mentioned in ancient books 12~45, the parts by weight of purslane 15~55, the parts by weight of dittany bark 15~55, the parts by weight of kuh-seng 12~45, dandelion
15~55 parts by weight.
4. Chinese medicine composition as claimed in claim 3, it is characterised in that the bulk drug of the Chinese medicine composition, which is constituted, is：It is yellow
The parts by weight of a kind of reed mentioned in ancient books 20, the parts by weight of purslane 30, the parts by weight of dittany bark 30, the parts by weight of kuh-seng 20, the parts by weight of dandelion 30；
Or, the parts by weight of radix scutellariae 25, the parts by weight of purslane 40, the parts by weight of dittany bark 35, the parts by weight of kuh-seng 30, the weight of dandelion 35
Part；
Or, the parts by weight of radix scutellariae 30, the parts by weight of purslane 35, the parts by weight of dittany bark 40, the parts by weight of kuh-seng 25, the weight of dandelion 40
Part.
5. the preparation method of Chinese medicine composition as described in claim any one of 1-4, it is characterised in that the preparation method is：Press
Ratio takes each bulk drug, and with water or organic solvent, routinely extracting method is extracted, and routinely preparation process is prepared into external application system
Agent.
6. preparation method as claimed in claim 5, it is characterised in that the exterior-applied formulation includes patch, cataplasm, ointment
Agent, plaster, gel, liniment, lotion, plastics.
7. a kind of Chinese medicine composition of external curing fash, it is characterised in that the Chinese medicine composition is made up of the following raw material medicine：
The parts by weight of Baical Skullcap root P.E 10~50, the parts by weight of purslane extract 10~60, the parts by weight of dittany bark extract 10~60, kuh-seng
The parts by weight of extract 10~50, the parts by weight of dandelion extract 10~60.
8. Chinese medicine composition as claimed in claim 7, it is characterised in that the Chinese medicine composition is made up of the following raw material medicine：
The parts by weight of Baical Skullcap root P.E 20, the parts by weight of purslane extract 30, the parts by weight of dittany bark extract 30, the weight of shrubby sophora extract 20
Part, the parts by weight of dandelion extract 30；
Or, the parts by weight of Baical Skullcap root P.E 25, the parts by weight of purslane extract 40, the parts by weight of dittany bark extract 35, kuh-seng extraction
The parts by weight of thing 30, the parts by weight of dandelion extract 35；
Or, the parts by weight of Baical Skullcap root P.E 30, the parts by weight of purslane extract 35, the parts by weight of dittany bark extract 40, kuh-seng extraction
The parts by weight of thing 25, the parts by weight of dandelion extract 40.
9. application of the Chinese medicine composition in external curing fash medicine is prepared as described in any one of claim 1-4,7-8.
10. the Chinese medicine composition as described in any one of claim 1-4,7-8 is prepared in the related fash medicines of external curing EGFRIs
Application.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710307137.5A CN107198718A (en) | 2017-05-04 | 2017-05-04 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
| CN201711010179.9A CN107617010B (en) | 2017-05-04 | 2017-10-25 | External traditional Chinese medicine composition for treating skin rash as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710307137.5A CN107198718A (en) | 2017-05-04 | 2017-05-04 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107198718A true CN107198718A (en) | 2017-09-26 |
Family
ID=59905549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710307137.5A Withdrawn CN107198718A (en) | 2017-05-04 | 2017-05-04 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
| CN201711010179.9A Active CN107617010B (en) | 2017-05-04 | 2017-10-25 | External traditional Chinese medicine composition for treating skin rash as well as preparation method and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711010179.9A Active CN107617010B (en) | 2017-05-04 | 2017-10-25 | External traditional Chinese medicine composition for treating skin rash as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN107198718A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107617010A (en) * | 2017-05-04 | 2018-01-23 | 常州桐树生物科技有限公司 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
| CN111166803A (en) * | 2020-01-13 | 2020-05-19 | 北京肿瘤医院(北京大学肿瘤医院) | Pure traditional Chinese medicine mask for relieving rash related to tumor-targeted medicine and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021506958A (en) | 2017-12-13 | 2021-02-22 | オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． | How to prevent or treat diseases associated with EGFR inhibition |
| CN114028568A (en) | 2018-04-16 | 2022-02-11 | 上海岸阔医药科技有限公司 | Method for preventing or treating side effects of tumor therapy |
| CN110787239B (en) * | 2019-12-20 | 2021-11-12 | 扬子江药业集团广州海瑞药业有限公司 | Traditional Chinese medicine composition for treating EGFR-TKIs (epidermal growth factor receptors-TKIs) related rashes and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105395651A (en) * | 2014-09-16 | 2016-03-16 | 贾志侠 | Anal eczema treating traditional Chinese medicine formula |
| CN104523944A (en) * | 2015-01-06 | 2015-04-22 | 中国人民解放军第二军医大学 | Traditional Chinese medicine for treating eczema and application thereof |
| CN105079186B (en) * | 2015-08-21 | 2018-06-22 | 中日友好医院 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
| CN107198718A (en) * | 2017-05-04 | 2017-09-26 | 常州桐树生物科技有限公司 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
-
2017
- 2017-05-04 CN CN201710307137.5A patent/CN107198718A/en not_active Withdrawn
- 2017-10-25 CN CN201711010179.9A patent/CN107617010B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107617010A (en) * | 2017-05-04 | 2018-01-23 | 常州桐树生物科技有限公司 | A kind of Chinese medicine composition of external curing fash and its preparation method and application |
| CN107617010B (en) * | 2017-05-04 | 2021-03-19 | 常州桐树生物科技有限公司 | External traditional Chinese medicine composition for treating skin rash as well as preparation method and application thereof |
| CN111166803A (en) * | 2020-01-13 | 2020-05-19 | 北京肿瘤医院(北京大学肿瘤医院) | Pure traditional Chinese medicine mask for relieving rash related to tumor-targeted medicine and preparation method thereof |
| CN111166803B (en) * | 2020-01-13 | 2021-07-23 | 北京肿瘤医院(北京大学肿瘤医院) | Pure traditional Chinese medicine mask for relieving rash related to tumor-targeted medicine and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107617010A (en) | 2018-01-23 |
| CN107617010B (en) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107198718A (en) | A kind of Chinese medicine composition of external curing fash and its preparation method and application | |
| CN106176784B (en) | It is a kind of for the pharmaceutical composition of dermatitis, application, preparation and preparation method thereof | |
| CN105079186B (en) | A kind of Chinese medicine composition of external curing fash and its preparation method and application | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN100998845A (en) | Chinese medicinal composition for treating mastopathy | |
| CN112353897A (en) | Skin antibacterial liquid and preparation method thereof | |
| CN104127743A (en) | Application of traditional Chinese medicinal lotion in preparation of tinea pedis treatment medicines | |
| CN108245602B (en) | A topical Chinese medicinal composition for treating dermatoses | |
| CN105213584A (en) | A kind of Chinese medicine composition for the treatment of eczema and preparation method thereof | |
| CN111375038B (en) | Traditional Chinese medicine bath composition for treating psoriasis as well as preparation method and application thereof | |
| CN1244353C (en) | Medicine for curing acne and its preparation method | |
| CN105616647A (en) | Traditional Chinese medicine composition containing Chinese mugwort leaves and used for treating eczema and preparation method thereof | |
| CN101181564A (en) | Chinese medicine compound preparations with antineoplastic activity | |
| CN104042631B (en) | Application of the Liushen Pills in preventing and treating Fungal Skin medicine is prepared | |
| CN103417906A (en) | Applications of compound mylabris traditional Chinese medicine composition and preparations thereof in preparing drugs for curing depression | |
| CN106619765A (en) | Pharmaceutical composition containing Marsdenia tenacissima extract product | |
| CN102357199A (en) | Traditional Chinese medicine for treating manus and tinea pedis | |
| CN110664968B (en) | Gold paste | |
| CN106880797A (en) | A kind of Chinese medicine preparation for treating psoriasis | |
| CN112353901A (en) | Pure traditional Chinese medicine transdermal liniment for treating diabetes and preparation method thereof | |
| CN100998752A (en) | Traditional Chinese medicine decoction for treating radiation stomatitis | |
| CN102488836B (en) | Medicine for treating bladder tumor | |
| CN115252729A (en) | Traditional Chinese medicine composition for treating diabetes and application thereof | |
| CN117562942A (en) | Traditional Chinese medicine composition for treating pulmonary nodules and thyroid nodules and preparation method thereof | |
| CN104940842A (en) | Traditional Chinese medicine combination for treating cerebral edema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170926 |
|
| WW01 | Invention patent application withdrawn after publication |